Acute graft versus host disease in skin

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
HDAC inhibitor 1 substance
Kinase inhibitor 1 substance
Unknown / small molecule 1 substance
BCL-2 inhibitor 1 substance
Phase II: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Medical University Of Vienna Academic
    VENETOCLAX
    2025-520545-74-00 1 country 2026 n=24
    Recruiting

Phase IV

1 trial
  • Novartis Pharma Services AG Commercial
    PANOBINOSTAT; RUXOLITINIB; SIREMADLIN
    2024-515283-31-00 4 countries 2015 n=33 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma Services AG Commercial 1 Phase IV 0
Medical University Of Vienna Academic 1 Phase II 1
New trials by year
2026
1
← All indication landscapes